Nuvation Bio Reports IBTROZI Achieves 50-Month Median Response In ROS1+ NSCLC, To Be Presented At AACR 2026

Nuvation Bio Inc. announced that its drug IBTROZI has achieved a median Duration of Response (DOR) of 50 months in TKI-naïve patients with advanced ROS1-positive non-small cell lung cancer (NSCLC), as of August 2025. The updated clinical data will be presented at the AACR Annual Meeting 2026, highlighting the efficacy and safety of IBTROZI and taletrectinib in both TKI-naïve and TKI-pretreated patients. This presentation follows nearly a year of additional follow-up data since IBTROZI's FDA approval in June 2025.